Research and Markets: Triple Analysis: Colorectal Cancer, Leukemia and Peptides: Each Part is Evaluated According to Stand

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/203b8b/triple_analysis_c) has announced the addition of the "Triple Analysis: Colorectal Cancer, Leukemia and Peptides" report to their offering.

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Leukemia and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer The colorectal cancer report part comprises defined and up to date development strategies for 156 colorectal cancer drugs within the portfolio of 108 investigators, from Preclinical to Marketed. This report part extensively analyses 120 identified targets of colorectal cancer drugs, organized into 105 drug target strategies, and assesses them in colorectal cancer. This part is based on the following publication: Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis

Part II: Leukemia The leukemia report part comprises defined and up to date development strategies for 175 leukemia drugs (>250 projects) within the portfolio of 126 investigators, from Preclinical to Marketed. Leukemia drugs are further dived into the sub-indications of ALL, AML, CLL, CML, HCL and MCL. This report part extensively analyses 136 identified targets of leukemia drugs, organized into 115 drug target strategies, and assesses them in leukemia. This part is based on the following publication: Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking

Part III: Peptides The peptide report part comprises defined and up to date development strategies for 145 cancer peptide drugs within the portfolio of 103 investigators, from Ceased to Marketed. This report part extensively analyses 125 identified targets of peptide drugs, organized into 103 drug target strategies, and assesses them in 52 different cancer indications. This part is based on the following publication: Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies pipeline and portfolio planning (PPP) in cancer by:

  • Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
  • Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drugs properties
  • Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
  • Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
  • Supporting development of integrative molecule, pathway and disease area strategies
  • Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Truncated

Part I: Colorectal Cancer

How to Use this Report

Drug Target Profiles of Colorectal Cancer Drugs (120 Drug Targets)

The Progression and Maturity of Colorectal Cancer Targets (105 Drug Target Strategies and 156 Drugs)

Targets by R&D Approach in Colorectal Cancer (8 Different Compound Strategies)

Colorectal Cancer Targets by Companies (108 Investigators)

Drug Index

Company Index

Part II: Leukemia

Introduction

Single Drug Target Benchmarking from the Leukemia Pipeline (136 Drug Targets)

The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Combinations Identified in the Leukemia Pipeline? (115 Drug Target Strategies and 175 Drugs)

Compound Strategies at Work: Competitive Benchmarking of Leukemia Pipeline by Type of Compound (7 Different Compound Strategies)

Portfolio Planning: Competitive Benchmarking of Leukemia Pipeline by Investigator (126 Investigators)

Drug Index

Company Index

Part III: Peptides

The Scope of this Report

The Competitive Advantage and Disadvantage of Peptide Drugs

Consider the Therapeutic Peptide Target for the Highest Therapeutic Outcome and Return on Investment (125 Drug Targets)

Emerging New Products to Established Ones: Drug Target Strategies of Peptides by their Highest Stage of Development in Oncology (103 Drug Target Strategies and 145 Peptide Drugs)

Selecting Cancer Indications for Peptide Drugs (52 Cancer Indications)

Pipeline and Portfolio Planning: Competitive Benchmarking of the Peptide Drug Pipeline in Oncology by Investigator (103 Investigators)

Disclaimer

Drug Index

Company Index

For more information visit http://www.researchandmarkets.com/research/203b8b/triple_analysis_c



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Clinical Trials  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.